OR WAIT null SECS
April 24, 2020
The vaccine will be based on a ReiThera-proprietary simian adenoviral vector with strong immunological potency and low pre-existing immunity in humans.
Emergent will offer up its drug substance manufacturing services with support by investments from Johnson & Johnson starting in 2020.
April 20, 2020
Through the agreement, BARDA will support the advancement of the vaccine candidate to FDA licensure and will handle all late-stage clinical development programs, as well as the scale-up of mRNA-1273 manufacture in 2020.
March 30, 2020
Pre-clinical immunization studies of iBio’s SARS-CoV-2 VLP candidates are being performed by Texas A&M.
February 18, 2020
WuXi Vaccines, WuXi Biologics’ joint venture with Shanghai Hile Bio-technology, has signed a 20-year vaccine manufacturing contract with a global vaccine leader for $3 billion.
Sanofi will use a recombinant DNA platform that produces a genetic match to proteins found on the surface of COVID-19 to formulate the vaccine.
November 12, 2019
The plant in Singen, Germany will be used for formulation, filling, and packaging of Takeda’s vaccine candidate.
November 02, 2019
PATH’s Microarray Patch Center of Excellence aims to accelerate transdermal patch technology for public health needs.
October 22, 2019
The transaction is anticipated to close by the end of 2019.
August 26, 2019
The new vaccine will offer protection against the Nipah virus after a single dose.